Surgical Clamps Collection

Medical Device Sector Picks Up in Q3:16

In the first eight months of 2016, 80 transactions were announced in the Medical Device sector, making it unlikely this year’s deal volume would surpass last year’s total of 114 deals. As the third quarter wraps up, the sector’s deal volume has reached 90 deals: 31 in Q1, 27 in Q2, and 32 as of […]

 

Directly below portrait of surgeons with oxygen mask in operatio

MACRA Is Spooking Physician Medical Groups

With a full quarter left to go in 2016, mergers and acquisitions in the Physician Medical Group sector have caught up to last year’s total number of transactions. In 2015, 89 deals were announced. Through September 26, 2016, the sector’s deal volume has reached 88. One factor contributing to the increase in activity is the...

This content is for Health Care M&A Membership and Health Care 60 Day Free Trial members only.
Log In Free Trial

 

 

Euro USD index stock charts over one hundred dollars background

Preliminary Data: Q3 M and A

There’s still one week left to go in the month of September, and the third quarter, but the trends have already established themselves. Merger and acquisition activity in health care dropped 20% compared with the previous quarter, down to 331 deals compared with 415 in Q2:16. The third quarter also pales in comparison to the same...

This content is for Health Care M&A Membership and Health Care 60 Day Free Trial members only.
Log In Free Trial
Green bullish key on keyboard

Allergan Is Bullish on Biotech

Ever since Allergan (NYSE: AGN) completed the $40.5 billion sale of its generics business to Teva Pharmaceutical Industries (NYSE: TEVA) on August 2, the pharma giant is targeting biotech companies with a vengeance. In September alone (and we’re only talking about three weeks at this point), the company has announced four deals, totalling $1.28 billion. Year-to-date, Allergan has announced […]

Test tubes closeup on blue background. Drops from test stick

Allergan Adds Tobira to Its GI Pipeline

Allergan plc (NYSE: AGN) shows no signs of slowing its acquisition pace this year, and just solidified its lead in therapeutics for nonalcoholic steatohepatitis (NASH), an incurable disease affecting approximately 5% of the U.S. population. The pharma giant announced its acquisition of Tobira Therapeutics Inc. (NASDAQ: TBRA), This transaction marks the company’s eighth in 2016, […]

pills an pill bottle on white background

Horizon Pharma Buys Raptor

For the week ending September 16, 2016, a combined $1.01 billion was spent on three pharmaceutical deals, one of which is also the largest pharmaceutical deal so far in September. Horizon Pharma plc (NASDAQ: HZNP), which develops, acquires and commercializes medicines for the treatment of arthritis, pain, inflammatory and/or orphan diseases, acquired Raptor Pharmaceuticals Corp. (NASDAQ: […]

Surgical Clamps Collection

Stryker’s Minimally Invasive Acquisitions

For a company that has targeted minimally invasive surgical products of late, Stryker Corporation (NYSE: SYK) has been highly visible in the acquisition arena this year. It started in February 2016. That month, the medical device giant announced three deals, totaling $2.03 billion. In April, three more acquisitions were announced, with only one disclosed price of $40.6 million....

This content is for Health Care M&A Membership and Health Care 60 Day Free Trial members only.
Log In Free Trial
genetics

Allergan Eyes Clinical-Stage Ocular Drugs

Allergan plc (NYSE: AGN) just purchased privately-held RetroSense Therapeutics LLC for $60 million in an all-cash transaction, with potential regulatory and commercialization milestone payments. Based in Ann Arbor Michigan, RetroSense is a clinical-stage biotechnology company focused on novel gene therapy approaches to restore vision in those suffering from blindness. Its lead development program, RST-001, is […]